Search SEC
Fundamental Analysis
28 matches · 10756 cached companies
| Company | Fundamental | Momentum | Acceleration | Confidence | Revenue Growth | ROIC | FCF Growth | Op Margin Delta | Share Growth | Dividend Yield | Dividend Years | Payout Ratio | P/E | Signals |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 80.6 | 100 | 100 | 77 | +49.33% | +24.15% | n/a | n/a | +2.63% | 0% | 0 | n/a | n/a | Operating leverage, ROIC expansion, Net debt reduction, Strong operating leverage |
| IOTSamsara Inc. | 67.1 | 100 | 100 | 86 | +41.34% | -1.28% | n/a | +55.62% | +4% | 0% | 0 | n/a | 469.41x | Gross margin expansion, Operating leverage, Net debt reduction |
| MARMARRIOTT INTERNATIONAL INC /MD/ | 71.2 | 57.9 | 57.9 | 79 | +8.12% | n/a | n/a | +2.2% | -4.75% | 0.78% | 5 | 27.6% | n/a | Operating leverage, Net debt reduction, Share count reduction, Strong operating leverage |
| BTCYBIOTRICITY INC. | 62.4 | 100 | 100 | 84 | +20.79% | n/a | n/a | n/a | -4.69% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, Share count reduction1 warning |
| PLXProtalix BioTherapeutics, Inc. | 67.8 | 100 | 100 | 77 | +92.42% | +70.46% | n/a | +158.55% | +7.76% | 0% | 0 | n/a | 9.09x | Gross margin expansion, Operating leverage, Net debt reduction2 warnings |
| BOLTBolt Biotherapeutics, Inc. | 55.6 | 100 | 60 | 91 | +10.06% | -1,724.06% | n/a | +437.3% | -11.81% | 0% | 0 | n/a | n/a | Operating leverage, Share count reduction1 warning |
| AIOTPowerfleet, Inc. | 55.1 | 100 | 94 | 91 | +50.39% | +1.03% | n/a | +2.57% | +1.5% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, ROIC expansion, Net debt reduction |
| PGOLPATRIOT GOLD CORP | 67.1 | 100 | 100 | 71 | +391.76% | n/a | n/a | -13.74% | +13.16% | 0% | 0 | n/a | 14.57x | Operating leverage, Net debt reduction1 warning |
| BTMDbiote Corp. | 50.2 | 22.8 | 22.8 | 84 | -6.72% | +100.51% | n/a | +46.31% | -22.53% | 0% | 0 | 6.39% | 4.64x | Share count reduction2 warnings |
| PBYIPUMA BIOTECHNOLOGY, INC. | 50.6 | 48.3 | 48.3 | 83 | -4.22% | +29.97% | n/a | +0.96% | +5.39% | 0% | 0 | n/a | 26.14x | Gross margin expansion, Net debt reduction2 warnings |
| ARQTArcutis Biotherapeutics, Inc. | 59.2 | 100 | 100 | 71 | +117.76% | +1.01% | n/a | n/a | +107,723.89% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, ROIC expansion, Net debt reduction1 warning |
| IOVAIOVANCE BIOTHERAPEUTICS, INC. | 55.3 | 100 | 100 | 69 | +113.42% | -63.76% | n/a | n/a | +39.43% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage2 warnings |
| FBIOFortress Biotech, Inc. | 44.7 | n/a | n/a | 69 | +23.53% | n/a | n/a | +180.05% | +20.19% | 0% | 0 | 9.74% | 0.49x | Net debt reduction2 warnings |
| FBIOPFortress Biotech, Inc. | 44.7 | n/a | n/a | 69 | +23.53% | n/a | n/a | +180.05% | +20.19% | 0% | 0 | 9.74% | 4.08x | Net debt reduction2 warnings |
| BRNSBarinthus Biotherapeutics plc. | 44.6 | n/a | n/a | 63 | +1,766.46% | n/a | n/a | n/a | n/a | 0% | 0 | n/a | n/a | Net debt reduction |
| ADPTAdaptive Biotechnologies Corp | 41.7 | 100 | 100 | 64 | +60.53% | n/a | n/a | +90.65% | +7.15% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, Net debt reduction2 warnings |
| PMCBPharmaCyte Biotech, Inc. | 43.2 | n/a | 0 | 62 | n/a | -25.48% | n/a | n/a | +54.25% | 0% | 0 | n/a | n/a | Net debt reduction2 warnings |
| VIRVir Biotechnology, Inc. | 38.7 | n/a | n/a | 64 | +270.58% | n/a | n/a | n/a | n/a | 0% | 0 | n/a | n/a | Net debt reduction |
| EDSAEdesa Biotech, Inc. | 34.9 | n/a | n/a | 63 | -49.74% | n/a | n/a | n/a | n/a | 0% | 0 | n/a | n/a | Gross margin expansion |
| LABSTANDARD BIOTOOLS INC. | 23.5 | 100 | 100 | 90 | -25.17% | -37.13% | n/a | -18.67% | +3.35% | 0% | 0 | n/a | n/a | Operating leverage, ROIC expansion, Net debt reduction |
| NWBONORTHWEST BIOTHERAPEUTICS INC | 28 | 100 | 100 | 71 | +10.79% | n/a | n/a | -10.08% | +20.81% | 0% | 0 | n/a | n/a | Operating leverage, Net debt reduction1 warning |
| SABSSAB Biotherapeutics, Inc. | 26.5 | 0 | 0 | 72 | -76.67% | -230.35% | n/a | n/a | +83.64% | 0% | 0 | n/a | n/a | Net debt reduction5 warnings |
| SABSWSAB Biotherapeutics, Inc. | 26.5 | 0 | 0 | 72 | -76.67% | -230.35% | n/a | n/a | +83.64% | 0% | 0 | n/a | n/a | Net debt reduction5 warnings |
| AXIMAXIM BIOTECHNOLOGIES, INC. | 21.8 | n/a | n/a | 68 | +932.81% | n/a | n/a | n/a | n/a | 0% | 0 | n/a | n/a | n/a1 warning |
| MBRXMoleculin Biotech, Inc. | 21.5 | n/a | 0 | 64 | n/a | -236.01% | n/a | n/a | n/a | 0% | 0 | n/a | n/a | Net debt reduction1 warning |
1-25 of 28